

Aortic Valve Disease: Catheter-based Therapies for Now and in the Future

Christopher J. Petit, MD

Division Chief, Pediatric Cardiology
Welton M. Gersony Professor of Pediatrics
Co-Director, NYP Children's Heart Center



Disclosures

None

Classic Dogma

- “Critical AS is a disaster”
- “BAV results in severe AI”
- “*Dysplastic* valves”
- “Balloons don’t work”

LV Function Pre-BAV



Anatomy Dictates Physiology

$$\Delta P = \frac{\text{Cardiac_Output}^2}{\text{AVA}^2 * SEP^2 * 44.3 * \text{HR}^2}$$

Natural History


Decade	No. of patients	Patient years of follow-up	Sudden deaths	All deaths
1st	24*	93	2	2 (8)†
2nd	20 + 15	213	2	3 (8)
3rd	12 + 17	182	0	2 (7)
1-3rd	56 + 32	488	4	7 (8)
4th	12 + 9	124	1/0	2/1 (14)
5th	15 + 9	125	0/2	3/3 (25)
6th	4 + 4	45	1/0	3/3 (75)
Total	87	782	8	22 (25)

14/39 infants (36%) died in the first 1-2 years of life

Campbell Br Heart J 1968

Un-Natural: Surgical Aortic Valvotomy

- Described by Mustard in 1963
- Incision of fused commissures
- Increase in opening area reduces gradient




W.T. Mustard, Can Med As J 1963


“Un-Natural” Cath

- Balloon aortic valvuloplasty (BAV) introduced in 1983
- 9 French balloon catheters

Case No.	Age (yr)	Before Valvuloplasty		
		LV (mm Hg)	Aorta (mm Hg)	psg (mm Hg)
1	10	200/8	115/84	85
2	4	161/12	84/63	77
3	13	240/10	78/54	162
4	9	230/8	100/75	130
5	2	165/5	115/40	50
6	16	270/4	112/67	158
7	2	165/6	92/56	73
8	2	155/4	100/52	55
9	19	170/4	99/70	71
10	8	180/3	118/72	62
11	12	300/8	115/64	135
12	12	320/20	101/67	219
13	3	270/8	160/72	110
14	7	210/20	100/67	110
15	17	192/20	120/86	72
16	4	190/22	86/46	104
17	11	212/5	101/52	132
18	8	330/16	107/72	223
19	16	284/15	138/99	146
20	14	199/10	115/75	84
21	4	264/7	106/68	158
22	8	170/12	73/50	97
23	10	180/8	87/49	93
Mean	9	220/10	105/65	113
±SD	±5	±54/6	±19/14	±48


Lababidi, AHJ 1984






Neonatal BAV Works





Hickey et al, JTCVS 2012


Balloons tear



Solymar et al, JTCVS 1992

Surgical Interest in Neonatal AS

- Technical skillset
- “tricuspidization”
- “leaflet augmentation”
- “shaving/thinning”








McMullan JTCVS 2010





What about valve morphology?

- Reviewed 27 years of BAV
- Categorized morphology
- Reviewed long term outcomes (5-15 years)
- Valve factors:
 - Number of leaflets
 - Thickness of leaflets
 - Orientation of fusions

	Functionally Bicuspid N=92 (63%)
	True Bicuspid N=13 (9%)
	Functionally Unicuspid N=20 (14%)
	True Unicuspid N=6 (4%)
	Dysplastic N=16 (11%)

Maskatia CCI 2013

Functionally Bicuspid Valves Have Best Outcomes



Maskatia et al, CCI 2013

Something (48%) is missing

Reviewed 27 years of BAV






Categorized morphology

Reviewed long term outcomes (5-15 years)



Valve factors:

- Number of
- T

No Description of Aortic Valve in 48% of patients pre-BAV
No Description of Valve morphology in 90% of patients post-BAV


	Functionally Bicuspid N=92 (63%)
	True Bicuspid N=9 (9%)
	Tricuspid N=10 (14%)
	True Unicuspid N=6 (4%)
	Dysplastic N=16 (11%)

Torture your imaging colleagues




Aortic Valve Classification


Functionally Unicuspid



Functionally Bicuspid




True Bicuspid




Petit, AJC 2016

Tear into Leaflet or Along Commissure?



Risk of AI Post-Balloon




What do I worry about?

- Severe aortic insufficiency
- Leaving residual AS
- Ventricular arrhythmias
- Mitral valve damage
- Vascular injury
- Stroke

What do I worry about?


- Severe aortic insufficiency **
- Leaving residual AS ***
- Ventricular arrhythmias *
- Mitral valve damage *
- Vascular injury *****
- Stroke *

Carotid Access




0.3-
0.8mm

Femoral artery




2.5 - 4.0mm diameter

Carotid artery



Transcatheter Aortic Valve Replacement - TAVI




Mortality and Reoperation Risk After Bioprosthetic Aortic Valve Replacement in Young Adults With Congenital Heart Disease





Stephanie M. Fuller, MD, MS,* Michele J. Borisuk, MSN, CPNP,[†] Lynn A. Sleeper, ScD,^{†,‡}
 Emile Bacha, MD,[§] Luke Burchill, MD,[¶] Kristine Guleserian, MD,^{**} Michel Ilbawi, MD,^{††}
 Anees Razzouk, MD,^{‡‡} Takeshi Shinkawa, MD,^{§§} Minmin Lu, MS,[†] and Christopher W. Baird, MD^{¶¶}

Survival post-Bioprosthetic AVR




Reintervention by Age






Sinha, Khan et al CCI 2019

TAVI in Children




Risk of Reintervention with TAVI



Conclusions

- BAV – effective palliation
- TAVI – solution for bailout situations
- Area of necessary partnership with CHD surgeons

Thank you



Mind the wire!

